Cargando…

Structural insights into engineering a T-cell receptor targeting MAGE-A10 with higher affinity and specificity for cancer immunotherapy

BACKGROUND: T-cell receptor (TCR) immunotherapy is becoming a viable modality in cancer treatment with efficacy in clinical trials. The safety of patients is paramount, so innovative cell engineering methods are being employed to exploit adaptive immunity while controlling the factors governing anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Simister, Philip C, Border, Ellen C, Vieira, João F, Pumphrey, Nicholas J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2022
Materias:	Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295655/ https://www.ncbi.nlm.nih.gov/pubmed/35851311 http://dx.doi.org/10.1136/jitc-2022-004600

Ejemplares similares

Development of a CD8 co-receptor independent T-cell receptor specific for tumor-associated antigen MAGE-A4 for next generation T-cell-based immunotherapy
por: Davari, Kathrin, et al.
Publicado: (2021)

In vivo therapeutic effects of affinity-improved-TCR engineered T-cells on HBV-related hepatocellular carcinoma
por: Liu, Qi, et al.
Publicado: (2020)

Challenges and next steps in the advancement of immunotherapy: summary of the 2018 and 2020 National Cancer Institute workshops on cell-based immunotherapy for solid tumors
por: Fogli, Laura K, et al.
Publicado: (2021)

Designed improvement to T-cell immunotherapy by multidimensional single cell profiling
por: Bandey, Irfan N, et al.
Publicado: (2021)

Immunotherapy reverses glioma-driven dysfunction of immune system homeostasis
por: DiVita Dean, Bayli, et al.
Publicado: (2023)

Chemical priming of natural killer cells with branched polyethylenimine for cancer immunotherapy
por: Choi, Seung Hee, et al.
Publicado: (2022)

High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies
por: Çınar, Özcan, et al.
Publicado: (2021)

Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer immunotherapy
por: Lin, Tsung-Yi, et al.
Publicado: (2021)

Computational model of CAR T-cell immunotherapy dissects and predicts leukemia patient responses at remission, resistance, and relapse
por: Liu, Lunan, et al.
Publicado: (2022)

Intratumoral pan-ErbB targeted CAR-T for head and neck squamous cell carcinoma: interim analysis of the T4 immunotherapy study
por: Papa, Sophie, et al.
Publicado: (2023)

Hypoxia-inducible lentiviral gene expression in engineered human macrophages
por: Chinn, Harrison K, et al.
Publicado: (2022)

High-affinity CD16 integration into a CRISPR/Cas9-edited CD38 locus augments CD38-directed antitumor activity of primary human natural killer cells
por: Clara, Joseph Andrew, et al.
Publicado: (2022)

Genetically engineered macrophages persist in solid tumors and locally deliver therapeutic proteins to activate immune responses
por: Brempelis, Katherine J, et al.
Publicado: (2020)

Potent ex vivo armed T cells using recombinant bispecific antibodies for adoptive immunotherapy with reduced cytokine release
por: Park, Jeong A, et al.
Publicado: (2021)

Antibody-induced erythrophagocyte reprogramming of Kupffer cells prevents anti-CD40 cancer immunotherapy-associated liver toxicity
por: Pfefferlé, Marc, et al.
Publicado: (2023)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

TCR-engineered adoptive cell therapy effectively treats intracranial murine glioblastoma
por: Schaettler, Maximilian O, et al.
Publicado: (2023)

CBLB ablation with CRISPR/Cas9 enhances cytotoxicity of human placental stem cell-derived NK cells for cancer immunotherapy
por: Guo, Xuan, et al.
Publicado: (2021)

Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy
por: Liu, Xin, et al.
Publicado: (2022)

Chimeric antigen receptor T-cells targeting IL-1RAP: a promising new cellular immunotherapy to treat acute myeloid leukemia
por: Trad, Rim, et al.
Publicado: (2022)

Insufficiency of compound immune checkpoint blockade to overcome engineered T cell exhaustion in pancreatic cancer
por: Stromnes, Ingunn M, et al.
Publicado: (2022)

Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design
por: Qin, Haiying, et al.
Publicado: (2021)

H3.3K27M mutation is not a suitable target for immunotherapy in HLA-A2(+) patients with diffuse midline glioma
por: Immisch, Lena, et al.
Publicado: (2022)

T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion
por: Morton, Laura T, et al.
Publicado: (2022)

Preclinical proof of concept for VivoVec, a lentiviral-based platform for in vivo CAR T-cell engineering
por: Michels, Kathryn R, et al.
Publicado: (2023)

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy
por: Xiong, Chengjie, et al.
Publicado: (2022)

Human macrophages engineered to secrete a bispecific T cell engager support antigen-dependent T cell responses to glioblastoma
por: Gardell, Jennifer L, et al.
Publicado: (2020)

CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency
por: Li, Feng, et al.
Publicado: (2020)

Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities
por: Christodoulou, Ilias, et al.
Publicado: (2021)

Engineering second-generation TCR-T cells by site-specific integration of TRAF-binding motifs into the CD247 locus
por: Lah, Sangjoon, et al.
Publicado: (2023)

Δ133p53α enhances metabolic and cellular fitness of TCR-engineered T cells and promotes superior antitumor immunity
por: Legscha, Kevin Jan, et al.
Publicado: (2021)

Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy
por: Anderson, Kristin G, et al.
Publicado: (2022)

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors
por: Lontos, Konstantinos, et al.
Publicado: (2023)

Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability
por: Tang, Jianghui, et al.
Publicado: (2023)

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial
por: Rob, Lukas, et al.
Publicado: (2022)

Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
por: Zhang, Chaoting, et al.
Publicado: (2021)

Combinatorial immunotherapy of N-803 (IL-15 superagonist) and dinutuximab with ex vivo expanded natural killer cells significantly enhances in vitro cytotoxicity against GD2(+) pediatric solid tumors and in vivo survival of xenografted immunodeficient NSG mice
por: Chu, Yaya, et al.
Publicado: (2021)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma
por: Makkouk, Amani, et al.
Publicado: (2021)

Low-dose interferon-alpha preconditioning and adoptive cell therapy in patients with metastatic melanoma refractory to standard (immune) therapies: a phase I/II study
por: Verdegaal, Els, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tl41rb4dkvm8614m43lbkq966v